Birdon progresses new boats for the Netherlands Birdon Group is progressing the build of Bridge Erection Boats (BEBs) for the Netherlands Army, with...
Vous n'êtes pas connecté
FDA accepts Mesoblast’s responses Biotech company Mesoblast has announced that the United States Food and Drug Administration (FDA) has accepted Mesoblast’s Biologics License Application (BLA) resubmission for Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). According to a statement, the FDA considers the resubmission to be a complete… The post Manufacturing news briefs – stories you might have missed appeared first on Australian Manufacturing Forum.
Birdon progresses new boats for the Netherlands Birdon Group is progressing the build of Bridge Erection Boats (BEBs) for the Netherlands Army, with...
Birdon progresses new boats for the Netherlands Birdon Group is progressing the build of Bridge Erection Boats (BEBs) for the Netherlands Army, with...
Critical minerals prospectus showcases 55 projects The federal government has launched a new digital Australian Critical Minerals Prospectus,...
Food Recycle crowdfunding food waste to animal feed technology A new science-based solution to the food waste problem is to be launched by Australian...
GT Recycling officially opens Geelong soft plastics plant Geelong, Victoria’s GT Recycling has officially opened its soft plastics recycling...
Bisalloy’s profit growth flat Wear resistant and armoured steel manufacturer Bisalloy Steel Group sales tonnes were impacted in FY24 in Australia by...
Bisalloy’s profit growth flat Wear resistant and armoured steel manufacturer Bisalloy Steel Group sales tonnes were impacted in FY24 in Australia by...
Seatransport to design ships with closed cell foam Gold Coast based Ship design group Seatransport has secured the approval and exclusive licence for...
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.